Applied Therapeutics (APLT) Set to Announce Quarterly Earnings on Monday

Applied Therapeutics (NASDAQ:APLT – Get Rating) is set to announce its earnings results on Monday, March 20th.

Applied Therapeutics Trading Up 5.5 %

Applied Therapeutics stock opened at $0.95 on Friday. The firm has a 50-day moving average of $1.02 and a 200-day moving average of $0.95. The firm has a market cap of $45.76 million, a P/E ratio of -0.29 and a beta of 1.90. Applied Therapeutics has a 1-year low of $0.50 and a 1-year high of $2.73.

Hedge Funds Weigh In On Applied Therapeutics

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new position in Applied Therapeutics in the first quarter worth about $70,000. Walleye Capital LLC raised its stake in Applied Therapeutics by 366.7% in the first quarter. Walleye Capital LLC now owns 52,273 shares of the company’s stock worth $110,000 after buying an additional 41,073 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Applied Therapeutics by 25.4% in the first quarter. Goldman Sachs Group Inc. now owns 94,664 shares of the company’s stock worth $200,000 after buying an additional 19,159 shares in the last quarter. Two Sigma Advisers LP raised its stake in Applied Therapeutics by 121.7% in the third quarter. Two Sigma Advisers LP now owns 249,200 shares of the company’s stock worth $232,000 after buying an additional 136,800 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Applied Therapeutics by 8.7% in the fourth quarter. Geode Capital Management LLC now owns 361,078 shares of the company’s stock worth $274,000 after buying an additional 29,012 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

About Applied Therapeutics

(Get Rating)

Applied Therapeutics, Inc is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.